drugset / Trial / NCT01377389
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if ipilimumab in combination with either Lupron® (leuprolide), Zoladex® (goserelin), or Firmagon® (degarelix) can affect prostate-specific antigen (PSA) levels in patients with prostate cancer. Researchers also want to learn if these drug combinations affect the body's immune system. The safety of these drug combinations will also be studied.
Timeline
- Start
- 2011-06-17
- Primary completion
- 2017-04-07
- Completion
- 2017-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 80 mg | Subcutaneous |
| Subject | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |
| Subject | Ipilimumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Leuprolide | Other / unclassified | 7.5 mg | Intramuscular |